The 8th ISCC
December 1 -2, 2003
Keidanren Hall
December 1, 2003 (Mon)
13:00–13:10
Haruo Sugano (Cancer Chemotherapy Center, Tokyo)
Welcome and Introduction
From Human Genome to Cancer Chemotherapy
Chairpersons: Robert H. Shoemaker (NCI-Frederick, USA)
Takashi
Tsuruo (Univ. Tokyo, Tokyo)
13:10–13:40
Jaap Verweij (Erasmus University Medical Center, Netherlands)
Is phenotype/genotype based dosing for irinotecan a feasible way of
dose-individualisation?
13:40–14:00
Saburo Sone (Univ. Tokushima, Tokushima) and Yusuke Nakamura (Univ. Tokyo, Tokyo)
Genetic predictor of EGF receptor-targeted therapy for non-small cell lung cancer
14:00–14:30
Yoshiji Fujita (Tokyo Medical University, Tokyo)
Proteome analysis of anticancer drug response
14:30–14:40
Discussion
14:40–15:00
Coffee Break
Molecular Targets in Cancer Chemotherapy (Part I)
Chairpersons: Jaap Verweij (Erasmus University Medical
Center, Netherlands)
Yoshimasa Uehara (National Institute of Infectious Diseases,
Tokyo)
15:00–15:30
Herbert M. Pinedo (VUmc Cancer Center Amsterdam, Netherlands)
Anti-VEGF drugs
15:30–15:50
Kiyohiko Hatake (Cancer Chemotherapy Center, Tokyo)
VEGFR2 inhibitor
15:50–16:20
Johann de Bono (Royal Marsden Hospital, UK)
Targeted therapy for the treatment of prostate cancer
16:20–16:50
Jean-Pierre Armand (Institut Gustave Roussy, France)
Sugen 11248
16:50–17:20
Joseph P. Eder (Dana-Farber Cancer Institute, USA)
Anti-angiogenic targets in drug development: target validation in clinical trials
17:20–17:30
Discussion
17:30–18:30
Mixer
December 2, 2003 (Tue)
Molecular Targets in Cancer Chemotherapy (Part II)
Chairpersons: Mace L. Rothenberg (Vanderbilt University
Medical Center, USA)
Ryuzo Ueda (Nagoya City Univ., Nagoya)
09:30–10:00
Robert H. Shoemaker (NCI-Frederick, USA)
Targeting transcription factors for cancer chemotherapy
10:00–10:30
Edward A. Sausville (DTP, NCI, USA)
Approaches to histone deacetylase inhibition and DNA methylation
10:30–11:00
Nagahiro Saijo (National Cancer Center Hospital, Tokyo)
What are problems for the negative phase III trials of molecular target based drugs?
11:00–11:10
Discussion
11:10–11:30
Coffee Break
New Drugs under Clinical Consideration (Part I)
Chairpersons: Herbert M. Pinedo (VUmc Cancer Center Amsterdam,
Netherlands)
Masahiro Fukuoka (Kinki Univ., Osaka)
11:30–11:50
Noboru Yamamoto (National Cancer Center Hospital, Tokyo)
ZD6474
11:50–12:20
Jeanette Wood (Novartis Pharma AG, Switzerland)
From drug discovery to the clinic; experiences with PTK787/ZK222584, a VEGF receptor tyrosine kinase inhibitor
12:20–12:50
Nikhil C. Munshi (Dana-Farber Cancer Institute, USA)
Thalidomide analogues
12:50–13:00
Discussion
13:00–14:00
Lunch Break
New Drugs under Clinical Consideration (Part II)
Chairpersons: Jean-Pierre Armand (Institut Gustave Roussy,
France)
Yoshiro Niitsu (Sapporo Medical Univ., Sapporo)
14:00–14:20
Hironobu Minami (National Cancer Center Hospital East, Kashiwa)
Raf kinase inhibitor, BAY 43-9006
14:20–14:50
Xiongwen Zhang (Shanghai Institute of Materia Medica, China)
Salvicine, a novel DNA topoisomerase inhibitor showing potent anti-MDR effect
14:50–15:10
Hideyuki Akaza (Univ. Tsukuba, Tsukuba)
Selective endothelin receptor antagonist for prostate cancer; a clinical aspect
15:10–15:40
Matthias Mueser (Merck KGaA, Germany)
The epidermal growth factor receptor-targeting monoclonal antibody/cetuximab in the treatment of cancer
15:40–15:50
Discussion
15:50–16:10
Coffee Break
Clinical Development of Anticancer Agents
Chairpersons: Edward A. Sausville (DTP, NCI, USA)
Yutaka
Ariyoshi (Aichi Hosp., Nagoya)
16:10–16:40
Yasuhiro Fujiwara (National Cancer Center Hospital, Tokyo)
The impact of the 2002 revision of Pharmaceutical Affairs Law : Introduction of investigator-initiated registration-directed clinical trials in Japan
16:40–17:10
Mace L. Rothenberg (Vanderbilt University Medical Center, USA)
Clinical development of molecular-targeted agents: challenges and opportunities
17:10–17:20
Discussion
17:20–17:30
Takashi Tsuruo (Univ. Tokyo, Tokyo)
Closing Remark
